Concepts (249)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiovascular Diseases | 15 | 2023 | 1128 | 3.530 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 10 | 2019 | 145 | 2.720 |
Why?
|
| Dyslipidemias | 5 | 2023 | 53 | 2.190 |
Why?
|
| Practice Guidelines as Topic | 10 | 2018 | 408 | 1.850 |
Why?
|
| Troponin T | 4 | 2019 | 81 | 1.730 |
Why?
|
| Risk Assessment | 12 | 2019 | 1429 | 1.680 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 3 | 2019 | 9 | 1.660 |
Why?
|
| Heart Failure | 6 | 2017 | 639 | 1.620 |
Why?
|
| Diabetes Mellitus | 7 | 2023 | 412 | 1.430 |
Why?
|
| Hypertension | 7 | 2023 | 960 | 1.320 |
Why?
|
| Myocardial Infarction | 7 | 2017 | 475 | 1.240 |
Why?
|
| Cardiology | 4 | 2017 | 99 | 1.230 |
Why?
|
| American Heart Association | 4 | 2017 | 87 | 1.220 |
Why?
|
| Cholesterol, LDL | 3 | 2019 | 173 | 1.210 |
Why?
|
| United States | 24 | 2023 | 3976 | 1.200 |
Why?
|
| Guideline Adherence | 7 | 2018 | 120 | 1.200 |
Why?
|
| Hospitalization | 4 | 2017 | 470 | 1.160 |
Why?
|
| Registries | 10 | 2019 | 298 | 1.160 |
Why?
|
| Atherosclerosis | 6 | 2022 | 766 | 1.140 |
Why?
|
| Football | 4 | 2014 | 79 | 1.120 |
Why?
|
| Retirement | 3 | 2014 | 13 | 1.060 |
Why?
|
| Male | 40 | 2023 | 19217 | 1.050 |
Why?
|
| Middle Aged | 30 | 2020 | 11839 | 1.040 |
Why?
|
| Cognition | 2 | 2019 | 556 | 0.990 |
Why?
|
| Humans | 50 | 2023 | 32114 | 0.980 |
Why?
|
| Female | 36 | 2023 | 20015 | 0.930 |
Why?
|
| Stroke Volume | 2 | 2017 | 348 | 0.910 |
Why?
|
| Risk Factors | 21 | 2019 | 3880 | 0.900 |
Why?
|
| Carotid Artery Diseases | 2 | 2014 | 114 | 0.880 |
Why?
|
| Coronary Artery Disease | 4 | 2016 | 401 | 0.850 |
Why?
|
| Lipoprotein(a) | 2 | 2019 | 21 | 0.800 |
Why?
|
| Intermittent Claudication | 2 | 2018 | 11 | 0.780 |
Why?
|
| Health Status | 4 | 2017 | 400 | 0.770 |
Why?
|
| Coronary Disease | 3 | 2016 | 211 | 0.750 |
Why?
|
| Cholesterol | 3 | 2017 | 252 | 0.740 |
Why?
|
| C-Reactive Protein | 3 | 2017 | 238 | 0.710 |
Why?
|
| Aged | 22 | 2019 | 10314 | 0.700 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 66 | 0.670 |
Why?
|
| Apolipoproteins B | 1 | 2019 | 46 | 0.660 |
Why?
|
| Cognition Disorders | 2 | 2019 | 385 | 0.640 |
Why?
|
| Obesity | 4 | 2023 | 1176 | 0.630 |
Why?
|
| Hyperlipoproteinemia Type II | 2 | 2016 | 17 | 0.630 |
Why?
|
| Cardiovascular Agents | 2 | 2016 | 23 | 0.620 |
Why?
|
| Time Factors | 13 | 2019 | 2151 | 0.600 |
Why?
|
| Hospital Costs | 1 | 2017 | 38 | 0.570 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 104 | 0.560 |
Why?
|
| Health Status Disparities | 1 | 2018 | 131 | 0.560 |
Why?
|
| Mortality | 1 | 2017 | 125 | 0.560 |
Why?
|
| Adult | 16 | 2023 | 9380 | 0.560 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 12 | 0.550 |
Why?
|
| Triglycerides | 1 | 2017 | 230 | 0.550 |
Why?
|
| Quality Indicators, Health Care | 2 | 2016 | 59 | 0.550 |
Why?
|
| Forecasting | 1 | 2017 | 143 | 0.550 |
Why?
|
| Peptide Fragments | 1 | 2019 | 399 | 0.540 |
Why?
|
| Cardiomyopathies | 1 | 2016 | 56 | 0.540 |
Why?
|
| Blood Pressure | 5 | 2020 | 845 | 0.540 |
Why?
|
| Inservice Training | 1 | 2016 | 12 | 0.530 |
Why?
|
| Body Mass Index | 3 | 2019 | 923 | 0.530 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2016 | 63 | 0.520 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 83 | 0.520 |
Why?
|
| Education, Medical, Continuing | 1 | 2016 | 55 | 0.520 |
Why?
|
| Apolipoprotein C-III | 1 | 2015 | 5 | 0.520 |
Why?
|
| Prospective Studies | 9 | 2019 | 2283 | 0.510 |
Why?
|
| Lipoprotein Lipase | 1 | 2015 | 14 | 0.510 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2016 | 357 | 0.510 |
Why?
|
| Exercise Therapy | 1 | 2018 | 270 | 0.510 |
Why?
|
| Proprotein Convertases | 1 | 2015 | 2 | 0.510 |
Why?
|
| Diabetes Complications | 1 | 2016 | 177 | 0.500 |
Why?
|
| Hypercholesterolemia | 1 | 2016 | 70 | 0.500 |
Why?
|
| Acute Coronary Syndrome | 1 | 2017 | 196 | 0.490 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 127 | 0.490 |
Why?
|
| Waist Circumference | 1 | 2014 | 90 | 0.480 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 166 | 0.480 |
Why?
|
| Comorbidity | 7 | 2017 | 566 | 0.470 |
Why?
|
| Occupations | 1 | 2014 | 10 | 0.470 |
Why?
|
| Ventricular Function, Left | 1 | 2016 | 245 | 0.470 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 184 | 0.460 |
Why?
|
| Neck | 1 | 2014 | 27 | 0.460 |
Why?
|
| Athletes | 1 | 2014 | 69 | 0.460 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 169 | 0.450 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2019 | 83 | 0.450 |
Why?
|
| European Continental Ancestry Group | 1 | 2018 | 1166 | 0.440 |
Why?
|
| Treatment Outcome | 11 | 2019 | 3306 | 0.410 |
Why?
|
| Incidence | 5 | 2019 | 1199 | 0.400 |
Why?
|
| African Americans | 1 | 2018 | 1425 | 0.370 |
Why?
|
| Lipids | 3 | 2017 | 232 | 0.350 |
Why?
|
| Prognosis | 4 | 2017 | 1497 | 0.350 |
Why?
|
| Cohort Studies | 5 | 2017 | 1817 | 0.350 |
Why?
|
| Drug-Eluting Stents | 3 | 2017 | 13 | 0.340 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 2265 | 0.340 |
Why?
|
| Calcinosis | 3 | 2014 | 146 | 0.340 |
Why?
|
| Stents | 3 | 2017 | 177 | 0.310 |
Why?
|
| Calcium | 3 | 2014 | 307 | 0.310 |
Why?
|
| Linear Models | 4 | 2017 | 449 | 0.310 |
Why?
|
| Logistic Models | 6 | 2017 | 783 | 0.310 |
Why?
|
| Prevalence | 6 | 2017 | 989 | 0.300 |
Why?
|
| Quality of Life | 3 | 2018 | 946 | 0.290 |
Why?
|
| Proportional Hazards Models | 4 | 2017 | 753 | 0.290 |
Why?
|
| Predictive Value of Tests | 4 | 2017 | 876 | 0.280 |
Why?
|
| Postprandial Period | 2 | 2016 | 10 | 0.270 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 242 | 0.270 |
Why?
|
| Chi-Square Distribution | 5 | 2017 | 297 | 0.260 |
Why?
|
| Decision Support Techniques | 2 | 2017 | 128 | 0.260 |
Why?
|
| Drug Prescriptions | 2 | 2016 | 54 | 0.260 |
Why?
|
| Coronary Angiography | 3 | 2017 | 153 | 0.260 |
Why?
|
| Metals | 2 | 2017 | 18 | 0.240 |
Why?
|
| Southeastern United States | 1 | 2023 | 79 | 0.220 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 684 | 0.220 |
Why?
|
| Family Practice | 1 | 2023 | 51 | 0.220 |
Why?
|
| Coronary Vessels | 2 | 2014 | 165 | 0.220 |
Why?
|
| Self Efficacy | 1 | 2023 | 78 | 0.220 |
Why?
|
| Medical History Taking | 1 | 2022 | 37 | 0.210 |
Why?
|
| Refugees | 1 | 2022 | 7 | 0.200 |
Why?
|
| India | 3 | 2016 | 61 | 0.200 |
Why?
|
| Odds Ratio | 4 | 2016 | 472 | 0.190 |
Why?
|
| Hemorrhage | 2 | 2019 | 100 | 0.190 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 3990 | 0.190 |
Why?
|
| Neuropsychological Tests | 2 | 2019 | 371 | 0.180 |
Why?
|
| Health Facilities | 1 | 2020 | 10 | 0.180 |
Why?
|
| North Carolina | 2 | 2023 | 1538 | 0.180 |
Why?
|
| Respiratory Tract Diseases | 1 | 2020 | 34 | 0.180 |
Why?
|
| Up-Regulation | 2 | 2017 | 189 | 0.180 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2020 | 28 | 0.170 |
Why?
|
| Protein Precursors | 1 | 2019 | 22 | 0.170 |
Why?
|
| Models, Statistical | 2 | 2017 | 175 | 0.170 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 18 | 0.170 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2019 | 35 | 0.170 |
Why?
|
| Emigration and Immigration | 1 | 2019 | 31 | 0.160 |
Why?
|
| Apolipoprotein E4 | 1 | 2019 | 63 | 0.160 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 291 | 0.160 |
Why?
|
| Thinness | 1 | 2019 | 33 | 0.160 |
Why?
|
| Severity of Illness Index | 4 | 2014 | 881 | 0.160 |
Why?
|
| Drug Therapy, Combination | 2 | 2017 | 288 | 0.160 |
Why?
|
| Secondary Prevention | 1 | 2019 | 63 | 0.160 |
Why?
|
| Cross-Sectional Studies | 3 | 2017 | 1542 | 0.160 |
Why?
|
| Lower Extremity | 1 | 2019 | 100 | 0.160 |
Why?
|
| Canada | 1 | 2018 | 56 | 0.150 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 582 | 0.150 |
Why?
|
| Cholesterol, HDL | 1 | 2017 | 177 | 0.140 |
Why?
|
| Coronary Restenosis | 2 | 2017 | 13 | 0.140 |
Why?
|
| Cause of Death | 1 | 2017 | 236 | 0.140 |
Why?
|
| Recovery of Function | 1 | 2018 | 199 | 0.140 |
Why?
|
| Exercise Tolerance | 1 | 2018 | 125 | 0.140 |
Why?
|
| Anticholesteremic Agents | 1 | 2017 | 39 | 0.140 |
Why?
|
| Patient Preference | 1 | 2017 | 47 | 0.140 |
Why?
|
| Drug Utilization | 1 | 2016 | 49 | 0.140 |
Why?
|
| Disease Management | 1 | 2017 | 126 | 0.130 |
Why?
|
| Heterozygote | 1 | 2016 | 59 | 0.130 |
Why?
|
| Texas | 1 | 2016 | 36 | 0.130 |
Why?
|
| Cerebrovascular Disorders | 1 | 2016 | 52 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2016 | 61 | 0.130 |
Why?
|
| Veterans | 1 | 2016 | 68 | 0.130 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2016 | 65 | 0.130 |
Why?
|
| Double-Blind Method | 1 | 2017 | 525 | 0.130 |
Why?
|
| Developing Countries | 1 | 2016 | 48 | 0.130 |
Why?
|
| Transients and Migrants | 1 | 2019 | 297 | 0.130 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 770 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 633 | 0.130 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 20 | 0.130 |
Why?
|
| Retrospective Studies | 3 | 2022 | 3510 | 0.130 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 135 | 0.130 |
Why?
|
| Monocytes | 1 | 2016 | 127 | 0.130 |
Why?
|
| Ambulatory Care | 1 | 2016 | 108 | 0.120 |
Why?
|
| Genetic Markers | 1 | 2015 | 124 | 0.120 |
Why?
|
| Feasibility Studies | 1 | 2016 | 294 | 0.120 |
Why?
|
| Brain Ischemia | 1 | 2016 | 146 | 0.120 |
Why?
|
| Hyperlipidemias | 1 | 2015 | 54 | 0.120 |
Why?
|
| Genetic Testing | 1 | 2015 | 96 | 0.120 |
Why?
|
| Alleles | 1 | 2015 | 248 | 0.120 |
Why?
|
| Societies, Medical | 1 | 2015 | 164 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 510 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2016 | 355 | 0.120 |
Why?
|
| Anthropometry | 1 | 2014 | 83 | 0.120 |
Why?
|
| Survival Rate | 1 | 2016 | 877 | 0.120 |
Why?
|
| Ultrasonography, Doppler | 1 | 2014 | 24 | 0.120 |
Why?
|
| Carotid Stenosis | 1 | 2014 | 58 | 0.120 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 352 | 0.110 |
Why?
|
| Angioplasty, Balloon | 1 | 2013 | 35 | 0.110 |
Why?
|
| Primary Health Care | 1 | 2016 | 227 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 1428 | 0.110 |
Why?
|
| Apoptosis | 1 | 2015 | 360 | 0.110 |
Why?
|
| Coronary Thrombosis | 1 | 2012 | 14 | 0.110 |
Why?
|
| Mutation | 1 | 2015 | 489 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2016 | 333 | 0.110 |
Why?
|
| Young Adult | 2 | 2017 | 2665 | 0.100 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 322 | 0.100 |
Why?
|
| Mass Screening | 1 | 2014 | 263 | 0.100 |
Why?
|
| Inflammation | 1 | 2014 | 530 | 0.090 |
Why?
|
| Nepal | 2 | 2020 | 9 | 0.090 |
Why?
|
| Thrombosis | 1 | 2011 | 73 | 0.090 |
Why?
|
| Smoking | 1 | 2014 | 528 | 0.090 |
Why?
|
| Stroke | 1 | 2015 | 585 | 0.090 |
Why?
|
| Prosthesis Design | 2 | 2017 | 97 | 0.060 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2022 | 17 | 0.050 |
Why?
|
| Bhutan | 1 | 2022 | 1 | 0.050 |
Why?
|
| Adolescent | 2 | 2022 | 3568 | 0.050 |
Why?
|
| Focus Groups | 1 | 2022 | 118 | 0.050 |
Why?
|
| Public Sector | 1 | 2020 | 2 | 0.050 |
Why?
|
| Private Sector | 1 | 2020 | 8 | 0.050 |
Why?
|
| Respiration Disorders | 1 | 2020 | 7 | 0.050 |
Why?
|
| World Health Organization | 1 | 2020 | 15 | 0.050 |
Why?
|
| Health Resources | 1 | 2020 | 33 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2022 | 161 | 0.040 |
Why?
|
| Health Surveys | 1 | 2020 | 198 | 0.040 |
Why?
|
| Urban Population | 1 | 2020 | 90 | 0.040 |
Why?
|
| Sweden | 1 | 2019 | 14 | 0.040 |
Why?
|
| Middle East | 1 | 2019 | 5 | 0.040 |
Why?
|
| Asia | 1 | 2019 | 19 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2019 | 49 | 0.040 |
Why?
|
| Policy Making | 1 | 2019 | 20 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2019 | 73 | 0.040 |
Why?
|
| Netherlands | 1 | 2018 | 22 | 0.040 |
Why?
|
| Australia | 1 | 2018 | 72 | 0.040 |
Why?
|
| Rural Population | 1 | 2020 | 277 | 0.040 |
Why?
|
| Spain | 1 | 2017 | 3 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2019 | 198 | 0.040 |
Why?
|
| Executive Function | 1 | 2017 | 57 | 0.040 |
Why?
|
| Missouri | 1 | 2017 | 21 | 0.040 |
Why?
|
| Retreatment | 1 | 2017 | 41 | 0.040 |
Why?
|
| Drug Costs | 1 | 2017 | 47 | 0.040 |
Why?
|
| Disease Progression | 1 | 2018 | 594 | 0.030 |
Why?
|
| Patient Participation | 1 | 2017 | 82 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2016 | 62 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2017 | 202 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 125 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 142 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2016 | 122 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 276 | 0.030 |
Why?
|
| Outpatients | 1 | 2015 | 57 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 218 | 0.030 |
Why?
|
| Endarterectomy, Carotid | 1 | 2014 | 30 | 0.030 |
Why?
|
| X-Ray Microtomography | 1 | 2014 | 41 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2014 | 40 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 105 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 93 | 0.030 |
Why?
|
| Phenotype | 1 | 2016 | 632 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 548 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 226 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 538 | 0.030 |
Why?
|
| Ticlopidine | 1 | 2012 | 17 | 0.030 |
Why?
|
| Myocardial Reperfusion | 1 | 2012 | 10 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 1189 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 835 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2012 | 149 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2012 | 73 | 0.030 |
Why?
|
| Propensity Score | 1 | 2011 | 39 | 0.020 |
Why?
|
| Sirolimus | 1 | 2011 | 33 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2011 | 67 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 263 | 0.020 |
Why?
|